These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 30212196)
21. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. G de la Torre B; Albericio F Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407 [TBL] [Abstract][Full Text] [Related]
22. Time-related differences in the physical property profiles of oral drugs. Leeson PD; Davis AM J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303 [TBL] [Abstract][Full Text] [Related]
23. A comparison of physiochemical property profiles of development and marketed oral drugs. Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035 [TBL] [Abstract][Full Text] [Related]
24. Molecular properties that influence oral drug-like behavior. Lajiness MS; Vieth M; Erickson J Curr Opin Drug Discov Devel; 2004 Jul; 7(4):470-7. PubMed ID: 15338956 [TBL] [Abstract][Full Text] [Related]
25. The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. Polanski J; Bogocz J; Tkocz A J Comput Aided Mol Des; 2016 May; 30(5):381-9. PubMed ID: 27125384 [TBL] [Abstract][Full Text] [Related]
26. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. Guimarães CR; Mathiowetz AM; Shalaeva M; Goetz G; Liras S J Chem Inf Model; 2012 Apr; 52(4):882-90. PubMed ID: 22394163 [TBL] [Abstract][Full Text] [Related]
27. Dependence of molecular properties on proteomic family for marketed oral drugs. Vieth M; Sutherland JJ J Med Chem; 2006 Jun; 49(12):3451-3. PubMed ID: 16759087 [TBL] [Abstract][Full Text] [Related]
28. Ask the experts: past, present and future of the rule of five. Baell J; Congreve M; Leeson P; Abad-Zapatero C Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089 [TBL] [Abstract][Full Text] [Related]
29. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. Hu Y; Bajorath J J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069 [TBL] [Abstract][Full Text] [Related]
30. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Talele TT; Khedkar SA; Rigby AC Curr Top Med Chem; 2010; 10(1):127-41. PubMed ID: 19929824 [TBL] [Abstract][Full Text] [Related]
31. Synthetic Approaches to New Drugs Approved during 2018. Flick AC; Leverett CA; Ding HX; McInturff E; Fink SJ; Helal CJ; DeForest JC; Morse PD; Mahapatra S; O'Donnell CJ J Med Chem; 2020 Oct; 63(19):10652-10704. PubMed ID: 32338902 [TBL] [Abstract][Full Text] [Related]
32. Selection criteria for drug-like compounds. Muegge I Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312 [TBL] [Abstract][Full Text] [Related]
33. Degraders early developability assessment: face-to-face with molecular properties. Ermondi G; Vallaro M; Caron G Drug Discov Today; 2020 Sep; 25(9):1585-1591. PubMed ID: 32565163 [TBL] [Abstract][Full Text] [Related]
34. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five. Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890 [TBL] [Abstract][Full Text] [Related]
35. Is there enough focus on lipophilicity in drug discovery? Lobo S Expert Opin Drug Discov; 2020 Mar; 15(3):261-263. PubMed ID: 31736369 [No Abstract] [Full Text] [Related]
36. Drug discovery beyond the 'rule-of-five'. Zhang MQ; Wilkinson B Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532 [TBL] [Abstract][Full Text] [Related]
37. Why we need to implement intramolecular hydrogen-bonding considerations in drug discovery. Caron G; Ermondi G Future Med Chem; 2017 Jan; 9(1):1-5. PubMed ID: 27957863 [No Abstract] [Full Text] [Related]
38. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
39. Softening the Rule of Five--where to draw the line? Petit J; Meurice N; Kaiser C; Maggiora G Bioorg Med Chem; 2012 Sep; 20(18):5343-51. PubMed ID: 22222160 [TBL] [Abstract][Full Text] [Related]
40. Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified? Mignani S; Rodrigues J; Tomas H; Jalal R; Singh PP; Majoral JP; Vishwakarma RA Drug Discov Today; 2018 Mar; 23(3):605-615. PubMed ID: 29330127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]